Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
Horizon Therapeutics (HZNP) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Horizon Therapeutics (HZNP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
by Zacks Equity Research
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor
by Zacks Equity Research
Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor
Top Ranked Momentum Stocks to Buy for August 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales
by Zacks Equity Research
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q2 revenues increase year over year.
Emergent BioSolutions' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.
4 Solid Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
Investors who have the tendency to take a high level of risk can choose momentum stocks.
Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
by Zacks Equity Research
Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
by Zacks Equity Research
Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.